Page 105 - 83_02

13. Park BK, Laverty H, Srivastava A, et al. Drug
bioactivation and protein adduct formation in the
pathogenesis of drug-induced toxicity. Chem Biol
Interact 2011; 192:30-36
14. Sakatis MZ, Reese MJ, Harrell AW, et al. Preclinical
strategy to reduce clinical hepatotoxicity using in vitro
bioactivation data for >200 compounds. Chem Res
Toxicol 2012; 25:2067-2082
15. Gomez-Lechon MJ, Tolosa L, Castell JV, et al.
Mechanism-based selection of compounds for the
development of innovative in vitro approaches to
hepatotoxicity studies in the LIINTOP project.
Toxicol In Vitro 2010; 24:1879-1889.
16. Gomez-Lechon MJ, Donato MT, Castell JV, et al.
Human hepatocytes as a tool for studying toxicity and
drug metabolism. Curr Drug Metab 2003; 4:292-312.
17. Gomez-Lechon MJ, Donato MT, Castell JV et al.
Human hepatocytes in primary culture: the choice to
investigate drug metabolism in man. Curr Drug Metab
2004; 5:443-462.
18. Gomez-Lechon MJ, Castell JV, Donato MT. An update
on metabolism studies using human hepatocytes in
primary culture. Expert Opin Drug Metab Toxicol
2008; 4:837-854.
19. Hewitt NJ, Gómez-Lechon MJ, Houston JB, et al.
Primary hepatocytes: current understanding of the
regulation of metabolic enzymes and transporter
proteins, and pharmaceutical practice for the use of
hepatocytes in metabolism, enzyme induction,
transporter, clearance, and hepatotoxicity studies.
Drug Metab Rev 2007; 39:159-234.
20. Kim HM, Han SB, Hyun BH, et al. Functional human
hepatocytes: isolation from small liver biopsy samples
and primary cultivation with liver-specific functions. J
Toxicol Sci 1995; 20:565-578.
21. Kienhuis AS, Wortelboer HM, Maas WJ, et al. A
sandwich-cultured rat hepatocyte system with
increased metabolic competence evaluated by gene
expression profiling. Toxicol In Vitro 2007; 21:892-
901.
22. Donato MT, Lahoz A, Castell JV, et al. Cell lines: a
tool for in vitro drug metabolism studies. Curr Drug
Metab 2008; 9:1-11.
23. Donato MT, Jover R, Gomez-Lechon MJ. Hepatic cell
lines for drug hepatotoxicity testing: limitations and
strategies to upgrade their metabolic competence by
gene engineering. Curr Drug Metab 2013; 14:946-968.
24. O'Brien PJ, Irwin W, Diaz D, et al.: High concordance
of drug-induced human hepatotoxicity with in vitro
cytotoxicity measured in a novel cell-based model
using high content screening. Arch Toxicol 2006;
80:580-604.
25. Tolosa L., Pinto S, Donato MT, et al. Development of
a Multiparametric Cell-based Protocol to Screen and
Classify the Hepatotoxicity Potential of Drugs.
Toxicol Sci 2012a; 127:187-198.
@Real Academia Nacional de Farmacia. Spain
26. Tolosa L, Gómez-Lechón MJ, Donato MT. High-
content screening technology for studying drug-
induced hepatotoxicity in cell models. Arch Toxicol.
2015a; 89:1007-1022.
27. Tolosa L, Carmona A, Castell JV, et al. High-content
screening of drug-induced mitochondrial impairment
in hepatic cells: effects of statins. Arch Toxicol.
2015b; 89:1847-1860.
28. Van den Hof WF, Coonen ML, van Herwijnen M, et
al. Classification of hepatotoxicants using HepG2
cells: A proof of principle study. Chem Res Toxicol
2014; 27:433-442.
29. Donato MT, Gómez-Lechón MJ, Tolosa L. Using
high-content screening technology for studying drug-
induced hepatotoxicity in preclinical studies. Expert
Opin Drug Discov. 2017; 12:201-211.
30. Nakamura K, Kato N, Aizawa K, et al. Expression of
albumin and cytochrome P450 enzymes in HepG2
cells cultured with a nanotechnology-based culture
plate with microfabricated scaffold. 2011;0
36:625633.
31. Ramaiahgari SC, den Braver MW, Herpers B, et al. A
3D in vitro model of differentiated HepG2 cell
spheroids with improved liver-like properties for
repeated dose high-throughput toxicity studies. Arch
Toxicol 2014; 88:1083-1095.
32. Tolosa L, Gómez-Lechón MJ, Jiménez N, et al.
Advantageous use of HepaRG cells for the screening
and mechanistic study of drug-induced steatosis.
Toxicol Appl Pharmacol. 2016b; 1:02:1-9.
33. Aninat C, Piton A, Glaise D, et al. Expression of
cytochromes P450, conjugating enzymes and nuclear
receptors in human hepatoma HepaRG cells. Drug
Metab Dispos 2006; 34:75-83.
34. Klein S, Mueller D, Schevchenko V, Noor F. Long-
term maintenance of HepaRG cells in serum-free
conditions and application in a repeated dose study. J
Appl Toxicol. 2014; 34:1078-1086.
35. Le Vee M, Noel G, Jouan E, et al. Polarized expression
of drug transporters in differentiated human hepatoma
HepaRG cells. Toxicol In Vitro 2013; 27:1979-86.
36. Mueller D, Kramer L, Hoffmann E, et al. 3D
organotypic HepaRG cultures as in vitro model for
acute and repeated dose toxicity studies. Toxicol In
Vitro 2014; 28:104-112.
37. Gustafsson F, Foster AJ, Sarda S, et al. A correlation
between the in vitro drug toxicity of drugs to cell lines
that express human P450s and their propensity to
cause liver injury in humans. Toxicol Sci 2014;
137:189-211.
38. Tolosa L, Donato MT, Pérez-Cataldo G, et al.
Upgrading cytochrome P450 activity in HepG2 cells
co-transfected with adenoviral vectors for drug
hepatotoxicity assessment. Toxicol In Vitro. 2012b;
26:1272-1277.
39. Tolosa L, Gómez-Lechón MJ, Pérez-Cataldo G, et al.
HepG2 cells simultaneously expressing five P450
265